Hevascol

Hevascol is a radiopaque contrast agent whose active ingredient is ethiodized oil. It is supplied as an injectable solution intended for intra‑arterial and intralymphatic administration. The product is marketed in the European Union and requires a prescription. As a contrast medium, Hevascol enhances the visibility of vascular and lymphatic structures during X‑ray based imaging procedures, facilitating diagnostic and interventional radiology in clinical practice and research.

Hevascol is employed as a contrast medium in several radiological procedures that require enhanced visualization of vascular or lymphatic pathways. - Lymphangiography to delineate lymphatic vessels and nodes. - Angiography for detailed imaging of arterial and venous structures. - Endovascular embolization procedures to occlude abnormal vessels or bleeding sites. - Interventional radiology techniques such as tumor perfusion studies. - Pre‑operative mapping of vascular anatomy in complex surgical planning. - Selective catheter‑based delivery of the agent during therapeutic procedures to assess flow dynamics. - Assessment of vascular leakage or fistula formation in post‑traumatic or postoperative settings.

Adverse reactions to Hevascol are generally related to the iodine content and the oily vehicle, and they may range from mild, transient symptoms to severe, potentially life‑threatening events, especially in patients with known sensitivities or underlying vascular disease. Monitoring during and after administration helps to identify and manage these events promptly. Common: - Transient warmth or flushing at the injection site. - Mild nausea or vomiting. - Headache or dizziness. - Temporary discoloration of urine. - Mild pain or pressure sensation during injection. - Transient increase in heart rate. Serious: - Allergic-type reactions such as urticaria, pruritus, or angio‑edema. - Acute pulmonary embolism from oil droplets. - Renal function impairment in susceptible patients. - Severe anaphylactic shock. - Thrombosis of treated vessel.

When using Hevascol, clinicians should observe several precautionary measures to minimize risk and ensure optimal imaging results. - Verify patient history for iodine allergy or prior adverse reactions to oil‑based contrast agents. - Assess renal function before administration, especially in patients with chronic kidney disease. - Use the lowest effective volume to achieve adequate opacification. - Avoid use in pregnant or breastfeeding women unless clearly indicated. - Ensure proper catheter placement to prevent extravasation. - Monitor vital signs and oxygen saturation during the procedure. - Have emergency resuscitation equipment readily available.

Hevascol may interact with other agents administered during diagnostic or therapeutic procedures, and certain combinations should be avoided or used with caution. Avoid: - Concurrent use of other iodine‑based contrast media, which can increase total iodine load and risk of toxicity. - Administration of high‑dose corticosteroids immediately before injection, which may alter vascular permeability and affect distribution. - Simultaneous infusion of hyperosmolar agents, which may increase the risk of endothelial damage. Use with caution: - Anticoagulant or antiplatelet therapy, as oil emboli could exacerbate bleeding tendencies. - Beta‑blockers or other cardiovascular drugs, because transient hemodynamic changes may be amplified. - Nephrotoxic medications, given the potential for renal impairment in susceptible patients.